Back to Dashboard

DZ2022J0004

Lymphoma•NCT07234162•Last updated: 2/17/2026

Recruiting

Study Design

Study Drug

Golidicitinib

Mechanism of Action

JAK 1

Sponsor

Unknown

Design

III

Control Arm

Pralatrexate(缺藥) Belinostat Gemcitabine Chidamide

Criteria

Inclusion Criteria

≥1 prior Tx

Age: Phase: III

Exclusion Criteria

Enrollment

Progress3 / 4

Contact Information

Principal Investigator

Unknown

Study Nurse

李佳玲

Contact Tel

4620